Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year to $199.9 million. The company’s full-year revenue guidance of $840 million at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $1.92 per share was 8.8% above analysts’ consensus estimates.
Is now the time to buy COLL? Find out in our full research report (it’s free for active Edge members).
Collegium Pharmaceutical (COLL) Q2 CY2026 Highlights:
- Revenue: $199.9 million vs analyst estimates of $201.2 million (6.3% year-on-year growth, 0.7% miss)
- Adjusted EPS: $1.92 vs analyst estimates of $1.77 (8.8% beat)
- Adjusted EBITDA: $113.8 million vs analyst estimates of $108.4 million (57% margin, 5% beat)
- The company lifted its revenue guidance for the full year to $840 million at the midpoint from $815 million, a 3.1% increase
- EBITDA guidance for the full year is $457.5 million at the midpoint, below analyst estimates of $482.8 million
- Operating Margin: 1.9%, down from 18.7% in the same quarter last year
- Market Capitalization: $944.1 million
StockStory’s Take
Collegium Pharmaceutical’s second quarter saw sales growth, but results missed Wall Street’s revenue expectations, leading to a negative market reaction. Management attributed top-line growth to the expansion of its ADHD business, notably Jornay PM’s 41% year-over-year revenue increase and broader prescriber reach. CEO Vikram Karnani stressed that the integration of recently acquired Azstarys was completed ahead of the crucial back-to-school season, reinforcing the company’s strategy to diversify beyond pain management. However, Karnani acknowledged that lower-than-anticipated revenues from the NUCYNTA pain franchise, due to pricing pressure on authorized generics, weighed on performance this quarter.
Looking ahead, Collegium’s guidance is driven by confidence in ADHD franchise momentum, particularly as both Jornay PM and Azstarys are expected to benefit from increased promotional activity and expanded sales coverage. Management believes the strategic focus on ADHD, coupled with further cost discipline and targeted investments in commercial infrastructure, will offset anticipated pressure in the pain portfolio. CFO Colleen Tupper noted, “We are updating our 2026 financial guidance primarily to reflect lower-than-expected full-year revenue for the NUCYNTA franchise, but our expectations for ADHD products remain robust.” The company also remains open to further M&A in CNS (central nervous system) and adjacent rare disease markets to support future growth.
Key Insights from Management’s Remarks
Management identified ADHD segment expansion and ongoing pain business challenges as central themes this quarter, with portfolio diversification and operational integration shaping results.
ADHD business momentum: Management highlighted double-digit growth for Jornay PM, citing increased prescriber engagement and the successful addition of Azstarys to the product lineup. The sales force expansion and new promotional campaigns have contributed to heightened awareness and trial among healthcare providers.
Azstarys acquisition integration: The acquisition of Azstarys was completed in May, with management emphasizing rapid integration and full sales force training ahead of the back-to-school season. The company expects complementary positioning of Jornay PM and Azstarys, targeting different patient needs within ADHD treatment, to drive future growth.
Pain portfolio pressure: The pain segment faced revenue headwinds, primarily from the NUCYNTA franchise, which experienced significant net price erosion for its authorized generic products. CFO Colleen Tupper confirmed that net pricing for these generics has now stabilized, but revenues for the pain business are expected to remain under pressure.
Belbuca formulary access win: Belbuca, a key pain management product, performed well with improved formulary access slated to begin in the fourth quarter. This expanded access is expected to support prescription growth in the near term, though management is monitoring potential generic entry risks post-2027.
Operational leverage and cost discipline: Management reported increased operating expenses related to acquisition costs, but noted strategic focus on SG&A discipline and leveraging commercial infrastructure to maximize returns from the ADHD portfolio while maintaining profitability.
Drivers of Future Performance
Collegium’s outlook is shaped by continued ADHD franchise growth, integration synergies, and ongoing pain segment headwinds.
ADHD franchise expansion: Management expects momentum in the ADHD segment, driven by increased physician awareness, expanded sales coverage, and differentiated product profiles for Jornay PM and Azstarys. Promotional strategies targeting the back-to-school season are anticipated to accelerate prescription growth, particularly in pediatric and adolescent populations.
Pain business stabilization: While the pain portfolio faces ongoing net price pressures, especially for NUCYNTA generics, management believes pricing has now stabilized. Continued growth in Belbuca and expanded formulary access could partially offset declines elsewhere, but the risk of generic entries in coming years remains a key uncertainty.
Capital deployment and business development: The company remains focused on disciplined capital allocation, with priorities including further business development in CNS and rare diseases, debt reduction, and opportunistic share repurchases. Management views additional M&A as a potential lever for portfolio diversification and long-term revenue durability.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will closely watch (1) prescription growth trends for both Jornay PM and Azstarys during the back-to-school season, (2) stabilization and potential recovery in pain portfolio revenues as pricing normalizes, and (3) execution on formulary access wins for Belbuca. Progress on further M&A or new product additions will also be important markers of management’s ability to deliver on diversification and growth objectives.
Collegium Pharmaceutical currently trades at $29.62, down from $35.74 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
Stocks That Trumped Tariffs
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.